A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 7 more changesShow less
    • Final enrollment: 55 participants (planned 94)
    • Trial arms changed: 9 → 7
    • Primary and study completion dates changed from estimate of Jun 2026 to Jul 1, 2026
    • Start date changed from estimate of Jun 2025 to Jun 4, 2025
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 2 of 14 entries
    • Site details revised
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.
Trial Details
NCT Number NCT07024602
Lead Sponsor Ascletis Pharma (China) Co., Limited
Conditions
(from sponsor)		 Plaque Psoriasis
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov